WO2001093804A3 - Conjugues du virus de l'hepatite c - Google Patents

Conjugues du virus de l'hepatite c Download PDF

Info

Publication number
WO2001093804A3
WO2001093804A3 PCT/US2001/017302 US0117302W WO0193804A3 WO 2001093804 A3 WO2001093804 A3 WO 2001093804A3 US 0117302 W US0117302 W US 0117302W WO 0193804 A3 WO0193804 A3 WO 0193804A3
Authority
WO
WIPO (PCT)
Prior art keywords
hcv
conjugates
hepatitis
mimotopes
protein
Prior art date
Application number
PCT/US2001/017302
Other languages
English (en)
Other versions
WO2001093804A2 (fr
Inventor
Anthony J Conley
Philip M Mckenna
Craig T Przysiecki
Paul M Keller
Original Assignee
Merck & Co Inc
Anthony J Conley
Philip M Mckenna
Craig T Przysiecki
Paul M Keller
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc, Anthony J Conley, Philip M Mckenna, Craig T Przysiecki, Paul M Keller filed Critical Merck & Co Inc
Priority to JP2002501378A priority Critical patent/JP2004509846A/ja
Priority to US10/296,353 priority patent/US20030224011A1/en
Priority to CA002409287A priority patent/CA2409287A1/fr
Priority to EP01939609A priority patent/EP1290230A4/fr
Publication of WO2001093804A2 publication Critical patent/WO2001093804A2/fr
Publication of WO2001093804A3 publication Critical patent/WO2001093804A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des conjugués du VHC, capables d'induire une réponse immunitaire reconnaissant différentes souches et variantes du VHC. Les conjugués contiennent un support de complexe polypeptidique ou protéique et un ou plusieurs mimotopes VHC. Les mimotopes VHC préférés sont à l'origine d'antigènes capables de produire des anticorps reconnaissant des domaines hypervariables de la protéine VHC E2.
PCT/US2001/017302 2000-06-02 2001-05-29 Conjugues du virus de l'hepatite c WO2001093804A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2002501378A JP2004509846A (ja) 2000-06-02 2001-05-29 肝炎ｃ型ウイルスコンジュゲート
US10/296,353 US20030224011A1 (en) 2001-05-29 2001-05-29 Hepatitis c virus conjugates
CA002409287A CA2409287A1 (fr) 2000-06-02 2001-05-29 Conjugues du virus de l'hepatite c
EP01939609A EP1290230A4 (fr) 2000-06-02 2001-05-29 Conjugues du virus de l'hepatite c

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20908900P 2000-06-02 2000-06-02
US60/209,089 2000-06-02

Publications (2)

Publication Number Publication Date
WO2001093804A2 WO2001093804A2 (fr) 2001-12-13
WO2001093804A3 true WO2001093804A3 (fr) 2002-05-23

Family

ID=22777281

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/017302 WO2001093804A2 (fr) 2000-06-02 2001-05-29 Conjugues du virus de l'hepatite c

Country Status (4)

Country Link
EP (1) EP1290230A4 (fr)
JP (1) JP2004509846A (fr)
CA (1) CA2409287A1 (fr)
WO (1) WO2001093804A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY144231A (en) 2003-12-17 2011-08-15 Wyeth Corp Aß IMMUNOGENIC PEPTIDE CARRIER CONJUGATES AND METHODS OF PRODUCING SAME
WO2005058968A1 (fr) * 2003-12-18 2005-06-30 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Procede de production d'un conjugue porteur de peptides a antigenicite elevee
EP1733231B1 (fr) * 2004-04-05 2011-05-04 Université Bordeaux 2 Peptides et peptidomimetiques se liant a cd23
WO2006124712A2 (fr) * 2005-05-16 2006-11-23 Merck & Co., Inc. Procede d'augmentation de l'immunigenicite des antigenes de plasmodium

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5709995A (en) * 1994-03-17 1998-01-20 The Scripps Research Institute Hepatitis C virus-derived peptides capable of inducing cytotoxic T lymphocyte responses

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2047073A1 (fr) * 1990-07-19 1992-01-20 William J. Leanza Vaccins coconjugues comportant une proteine immunogene, des peptides lies a vih et des fractions anioniques
US5274122A (en) * 1992-10-15 1993-12-28 Merck & Co., Inc. Acidic derivatives of homocysteine thiolactone
AU3714499A (en) * 1998-05-14 1999-11-29 Pasteur Merieux Serums Et Vaccins Hepatitis c virus mimotopes
GB9810756D0 (en) * 1998-05-19 1998-07-15 Angeletti P Ist Richerche Bio Mimotopes of hypervariable region 1 of the e2 glycoprotein of hcv and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5709995A (en) * 1994-03-17 1998-01-20 The Scripps Research Institute Hepatitis C virus-derived peptides capable of inducing cytotoxic T lymphocyte responses

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1290230A4 *

Also Published As

Publication number Publication date
CA2409287A1 (fr) 2001-12-13
EP1290230A4 (fr) 2004-10-20
JP2004509846A (ja) 2004-04-02
EP1290230A2 (fr) 2003-03-12
WO2001093804A2 (fr) 2001-12-13

Similar Documents

Publication Publication Date Title
WO1993000365A3 (fr) Polypeptides utilises dans la lutte contre le virus de l'hepatite c
DE69938054D1 (de) Antikörpervarianten mit höheren bindungsaffinitäten im vergleich zu parentalen antikörpern
HUP0303134A3 (en) Hiv peptides, antigens, vaccine compositions, immunoassay kits and method of detecting antibodies induced by hiv
NZ219113A (en) Hiv peptide containing epitope of the env protein
GR940300008T1 (fr)
WO2001098333A3 (fr) Modification de l'antigene capsidique de l'hepatite b
HUP0200265A2 (en) Hiv peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by hiv
WO2002074795A3 (fr) Complexes de proteines oligomeres recombinantes a potentiel immunogene ameliore
PT666916E (pt) Antigenes de plasmodium falciparum inductores de anticorpos protectores
WO1999050301A3 (fr) Epitopes de proteines enveloppes virales, anticorps specifiques de ces proteines et leur utilisation dans la detection d'antigenes du vhc dans des tissus hotes
NZ518999A (en) Vaccine compositions
HK1013849A1 (en) An augmented western blot format and immunoassay for detection of viral antibodies
NO20051715L (no) HCV assay
EP1412538A4 (fr) Procedes servant a detecter simultanement des antigenes de hcv et des anticorps anti-hcv
GB9810756D0 (en) Mimotopes of hypervariable region 1 of the e2 glycoprotein of hcv and uses thereof
WO2002057314A3 (fr) Prevention et traitement d'une infection par le virus de l'hepatite c au moyen d'anticorps diriges contre des epitopes conformationnels
WO2001093804A3 (fr) Conjugues du virus de l'hepatite c
WO2002055560A3 (fr) Anticorps monoclonaux specifiques a la glycoproteine e2 du virus de l'hepatite c et leurs utilisations dans le diagnostic, le traitement et la prevention de l'hepatite c
EP1326895B8 (fr) Anticorps monoclonaux diriges contre des virus de l'hepatite b
WO2003040341A3 (fr) Anticorps contre le virus de l'hepatite a
AU2001286669A1 (en) Oral fluid rapid assay for hepatitis c virus (hcv) antibodies using non-antibody labeling of iga molecules recognizing hcv peptide epitopes
EP0870830A3 (fr) Antigene chimérique derivé du virus de l'hépatite C
GR970300022T1 (en) Peptide capable of being recognised by antibodies recognising the C33 antigen of hepatitis C virus
WO2002060390A3 (fr) Induction de reponses immunitaires a des antigenes modifies a l'isoaspartyle
WO2001092321A3 (fr) Proteines intervenant dans la cytoadhesion de plasmodium falciparum d'erythrocytes infectes au stade annulaire, anticorps se liant aux proteines, methodes de detection de l'infection, de stades de l'infection, et vaccins pour la protection contre l'infection

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

WWE Wipo information: entry into national phase

Ref document number: 2409287

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001939609

Country of ref document: EP

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2002 501378

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 10296353

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2001939609

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2001939609

Country of ref document: EP